“The Venteicher laboratory develops experimental and computational approaches to study how reversible changes in DNA organization drive cell fate decisions both in neurodevelopment and in brain cancer. The generous support of the Sontag Foundation’s Distinguished Scientist Award allows us to push towards translating research findings into the clinic to advance the standard of care for brain tumor patients. We are grateful to be part of the Sontag family."
- Dr. Andrew S. Venteicher
- Assistant Professor, Department of Neurosurgery, University of Minnesota, Minneapolis, MN
- Neurosurgical Co-director, Center for Skull Base/Pituitary Surgery, University of Minnesota, Minneapolis, MN
- Program Co-lead, Skull Base/Pituitary Surgery, MHealth-Fairview Health System, Minneapolis, MN
About DSA-Funded Research
Tumor heterogeneity, the differences between cells within a patient’s tumor, provides a formidable challenge in the treatment of brain cancer. Heterogeneity fuels tumor evolution and immune evasion, and thus thwarts our ability to design effective drug therapy. Tumor heterogeneity relies in large part on DNA structure and resulting differences in gene expression in individual cells. To date, however, the means by which tumor cells accomplish this remains incompletely understood. A major barrier to understanding these processes is the technological hurdle of measuring how the DNA is organized and which genes are expressed in actual patient tumors. We apply new biochemistry, genomics, single cell, and computational approaches to tumor specimens from patients, which reveals aspects of tumor heterogeneity not fully replicated in model systems. We seek to take what we are learning to develop new diagnostic and therapeutic strategies that can be translated into the clinic rapidly.
"Andrew is incredibly bright and creative. It is highly unusual for someone with his level of scientific aptitude and accomplishments to be clinically trained, and even rarer for him to be a highly skilled neurosurgeon."
Dr. Steven Artandi
Stanford Cancer Institute
"Andrew is that rare clinician scientist who will apply scientific rigor to problems of direct medical relevance. He is an excellent clinical neurosurgeon with the mindset of a scientist, who plans on devoting his life to scientific inquiries that shape the interface between intellectual pursuits and palliating human suffering."
Dr. Clark Chen
University of Minnesota Medical School